Small-cell carcinoma

Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

Retrieved on:

Monday, January 4, 2021

Infectious causes of cancer, Medical specialties, Clinical medicine, Neuroendocrinology, Oncology, DLL3, Neuroendocrine tumor, Small-cell carcinoma, Endocrine oncology, Cancer, Prostate cancer, Lung cancer

Treatment options for small cell lung cancer are limited, as are options for other DLL3-associated tumors such as neuroendocrine prostate cancer.

Key Points:

Treatment options for small cell lung cancer are limited, as are options for other DLL3-associated tumors such as neuroendocrine prostate cancer.
We are excited to participate in this trial of a promising agent that will hopefully benefit patients with small cell lung cancer and other neuroendocrine tumors, said Melissa Johnson, M.D., Program Director of Lung Cancer Research at Sarah Cannon Research Institute.
HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors.
These forward-looking statements are based on Harpoon Therapeutics expectations and assumptions as of the date of this press release.

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...

Retrieved on:

Monday, November 9, 2020

KEYTRUDA monotherapy remains a standard of care for the treatment of certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1.

Key Points:

KEYTRUDA monotherapy remains a standard of care for the treatment of certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1.
Merck has an extensive clinical development program in lung cancer and is advancing multiple registration-enabling studies with KEYTRUDA in combination with other treatments and as monotherapy.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Retrieved on:

Monday, November 9, 2020

Lung cancer, Cancer, Clinical medicine, Neoplasms, Non-small-cell lung carcinoma, Small-cell carcinoma, CimaVax-EGF, Treatment of lung cancer

At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.

Key Points:

At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.
Cosibelimab appeared to be safe and well-tolerated with a potentially favorable safety profile as compared to anti-PD-1 therapies currently available.
A copy of the poster presentation is available on the Publications page of the Pipeline section of Checkpoints website, www.checkpointtx.com .
According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2020, and non-small cell lung cancer accounts for 80-85% of all lung cancers.

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Retrieved on:

Friday, November 6, 2020

The combination of Opdivo plus Yervoy has previously demonstrated long-term survival outcomes across multiple cancer types, including melanoma and renal cell carcinoma.

Key Points:

The combination of Opdivo plus Yervoy has previously demonstrated long-term survival outcomes across multiple cancer types, including melanoma and renal cell carcinoma.
We are pleased to see new treatment options approved that may potentially help more people with metastatic non-small cell lung cancer.''
ORR was significantly higher for Opdivo plus Yervoy with two cycles of chemotherapy vs. chemotherapy alone: 38% vs. 25% (p=0.0003).
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer and accounts for up to 84% of diagnoses.

Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Retrieved on:

Thursday, October 29, 2020

Biotechnology, Pharmaceutical, Oncology, Health, FDA, Diabetes, Clinical trials, Other Health, Lung cancer, Clinical medicine, Cancer, Neoplasms, Non-small-cell lung carcinoma, Osimertinib, Small-cell carcinoma, T790M, Treatment of lung cancer

We are very pleased to receive FDAs conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer, said Rodney Varner, President and Chief Executive Officer of Genprex.

Key Points:

We are very pleased to receive FDAs conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer, said Rodney Varner, President and Chief Executive Officer of Genprex.
Final approval of the REQORSA brand name is conditional on FDA approval of the product candidate.
In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZenecas Tagrisso for the treatment of non-small cell lung cancer.
The Companys lead product candidate, REQORSA immunogene therapy drug (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

Retrieved on:

Monday, October 26, 2020

Drugs, Cancer, Clinical medicine, Monoclonal antibodies, Carcinoma, Cytopathology, Lung cancer, Small-cell carcinoma, Mapatumumab, Tigatuzumab

During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.

Key Points:

During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.
The phase III clinical trial of sugemalimab in patients with stage IV non-small cell lung cancer has reached its primary endpoint.
CStone plans to submit a new drug application to the National Medical Products Administration of China soon.
EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society.

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

Retrieved on:

Monday, October 26, 2020

Drugs, Cancer, Clinical medicine, Monoclonal antibodies, Carcinoma, Cytopathology, Lung cancer, Small-cell carcinoma, Mapatumumab, Tigatuzumab

During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.

Key Points:

During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.
The phase III clinical trial of sugemalimab in patients with stage IV non-small cell lung cancer has reached its primary endpoint.
CStone plans to submit a new drug application to the National Medical Products Administration of China soon.
EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society.

Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer

Retrieved on:

Monday, October 19, 2020

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Clinical medicine, Senescence, Cancer, Telomerase, Small-cell carcinoma, Lung cancer, Non-small-cell lung carcinoma, UV1, UV1 Clinical Programs, Ultimovacs

Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer.

Key Points:

Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer.
The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term survival benefit.
Non-small cell lung cancer highly expresses telomerase and remains an indication in great need of new treatment options for patients.
As a universal cancer vaccine, UV1s unique mechanism of action has the potential to be applicable across most cancer types.

Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer

Retrieved on:

Friday, October 16, 2020

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.

Key Points:

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
Quavonlimab is currently being evaluated in combination with KEYTRUDA across multiple solid tumors as part of ongoing Phase 1 and 2 trials.
A Phase 3 trial of quavonlimab coformulated with KEYTRUDA in advanced non-small cell lung cancer is planned.
KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

Retrieved on:

Wednesday, October 7, 2020

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Clinical medicine, Drugs, Cancer, Breakthrough therapy, RTT, Infectious causes of cancer, Monoclonal antibodies, Non-small-cell lung carcinoma, Nivolumab, Small-cell carcinoma, Bladder cancer, Lung cancer

To date, Opdivo has shown improved efficacy in the neoadjuvant or adjuvant treatment of four tumor types: lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.

Key Points:

To date, Opdivo has shown improved efficacy in the neoadjuvant or adjuvant treatment of four tumor types: lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.
CheckMate -816 is a Phase 3 randomized, open label, multi-center trial evaluating Opdivo plus chemotherapy compared to chemotherapy alone as neoadjuvant treatment in patients with resectable non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer, representing up to 84% of diagnoses.
OPDIVO (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.